Evidence map›Paper›PMID 25799064›Full record

ArticlePLoS pathogens2015

The RNA template channel of the RNA-dependent RNA polymerase as a target for development of antiviral therapy of multiple genera within a virus family.

Lonneke van der Linden, Laia Vives-Adrián, Barbara Selisko, Cristina Ferrer-Orta, Xinran Liu, Kjerstin Lanke, Rachel Ulferts, Armando M De Palma, Federica Tanchis, Nesya Goris and 13 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Enterovirus A71 antivirals: Past, present, and future.Acta pharmaceutica Sinica. B · 2022
    Article
  17. Review
  18. Article
  19. Review
  20. CScientific reports · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 6 countries.

Lonneke van der LindenDepartment of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands; Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
Laia Vives-AdriánInstitut de Biologia Molecular de Barcelona (CSIC), Parc Científic de Barcelona, Barcelona, Spain.
Barbara SeliskoAFMB UMR 7257, Aix-Marseille Université & CNRS, Marseille, France.
Cristina Ferrer-OrtaInstitut de Biologia Molecular de Barcelona (CSIC), Parc Científic de Barcelona, Barcelona, Spain.
Xinran LiuDepartment of Chemistry, Pennsylvania State University, University Park, Pennsylvania, United States of America.
Kjerstin LankeDepartment of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Rachel UlfertsDepartment of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands; Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Armando M De PalmaLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
Federica TanchisAbteilung Pharmazeutische Chemie, Institut für Pharmazie, Universität Innsbruck, Innsbruck, Austria.
Nesya GorisOkapi Sciences NV, Heverlee, Belgium.
David LefebvreUnit of Vesicular and Exotic Diseases, Virology Department, CODA-CERVA, Veterinary and Agrochemical Research Centre, Brussels, Belgium.
Kris De ClercqUnit of Vesicular and Exotic Diseases, Virology Department, CODA-CERVA, Veterinary and Agrochemical Research Centre, Brussels, Belgium.
Pieter LeyssenLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
Céline LacroixLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
Gerhard PürstingerAbteilung Pharmazeutische Chemie, Institut für Pharmazie, Universität Innsbruck, Innsbruck, Austria.
Bruno CoutardAFMB UMR 7257, Aix-Marseille Université & CNRS, Marseille, France.
Bruno CanardAFMB UMR 7257, Aix-Marseille Université & CNRS, Marseille, France.
David D BoehrDepartment of Chemistry, Pennsylvania State University, University Park, Pennsylvania, United States of America.
Jamie J ArnoldDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania, United States of America.
Craig E CameronDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania, United States of America.
Nuria VerdaguerInstitut de Biologia Molecular de Barcelona (CSIC), Parc Científic de Barcelona, Barcelona, Spain.
Johan NeytsLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
Frank J M van KuppeveldDepartment of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands; Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Pennsylvania State University · USInstitut de Biologia Molecular de Barcelona · ESKU Leuven · BECentre National de la Recherche Scientifique · FRRadboud University Medical Center · NLRega Institute for Medical Research · BEUniversität Innsbruck · ATVeterinary and Agrochemical Research Centre · BEAix-Marseille Université · FRRadboud Institute for Molecular Life Sciences · NL

Funding

Watching Conformational Rearrangements in Poliovirus RNA-Dependent RNA PolymeraseR01AI104878 · NIAID · PENNSYLVANIA STATE UNIVERSITY, THE · PI BOEHR, DAVID DOUGLAS · 2014 to 2024
$3.0M
NIAID NIH HHS R01 AI104878
6 · The paper itself

Abstract

The genus Enterovirus of the family Picornaviridae contains many important human pathogens (e.g., poliovirus, coxsackievirus, rhinovirus, and enterovirus 71) for which no antiviral drugs are available. The viral RNA-dependent RNA polymerase is an attractive target for antiviral therapy. Nucleoside-based inhibitors have broad-spectrum activity but often exhibit off-target effects. Most non-nucleoside inhibitors (NNIs) target surface cavities, which are structurally more flexible than the nucleotide-binding pocket, and hence have a more narrow spectrum of activity and are more prone to resistance development. Here, we report a novel NNI, GPC-N114 (2,2'-[(4-chloro-1,2-phenylene)bis(oxy)]bis(5-nitro-benzonitrile)) with broad-spectrum activity against enteroviruses and cardioviruses (another genus in the picornavirus family). Surprisingly, coxsackievirus B3 (CVB3) and poliovirus displayed a high genetic barrier to resistance against GPC-N114. By contrast, EMCV, a cardiovirus, rapidly acquired resistance due to mutations in 3Dpol. In vitro polymerase activity assays showed that GPC-N114 i) inhibited the elongation activity of recombinant CVB3 and EMCV 3Dpol, (ii) had reduced activity against EMCV 3Dpol with the resistance mutations, and (iii) was most efficient in inhibiting 3Dpol when added before the RNA template-primer duplex. Elucidation of a crystal structure of the inhibitor bound to CVB3 3Dpol confirmed the RNA-binding channel as the target for GPC-N114. Docking studies of the compound into the crystal structures of the compound-resistant EMCV 3Dpol mutants suggested that the resistant phenotype is due to subtle changes that interfere with the binding of GPC-N114 but not of the RNA template-primer. In conclusion, this study presents the first NNI that targets the RNA template channel of the picornavirus polymerase and identifies a new pocket that can be used for the design of broad-spectrum inhibitors. Moreover, this study provides important new insight into the plasticity of picornavirus polymerases at the template binding site.

Indexed as

AnimalsAntiviral AgentsBinding SitesCardiovirusChlorocebus aethiopsEnterovirus B, HumanHeLa CellsHumansPoliovirusRNA-Dependent RNA PolymeraseViral ProteinsAntiviral AgentsRNA-Dependent RNA PolymeraseViral Proteins

Identifiers

PMID25799064
PMCPMC4370873
OpenAlexW2009178147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.